Why the study?
Does nisoldipine prevent hypertension, cardiac hypertrophy, and elevated ANP levels in spontaneously hypertensive rats?
Does nisoldipine prevent hypertension, cardiac hypertrophy, and elevated ANP levels in spontaneously hypertensive rats?
Answers are grounded in this paper and cite their sources.
Nisoldipine prevents the development of hypertension and cardiac hypertrophy, and reduces elevated ANP levels in spontaneously hypertensive rats, including those with end-stage heart failure.
The effect of long-term treatment with the calcium antagonist nisoldipine on development of hypertension, cardiac hypertrophy, and plasma levels of atrial natriuretic peptides (ANP) was determined in spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) of the same age. Measurement of immunoreactive ANP in plasma provided a sensitive marker for the severity of hypertension and the associated cardiac overload. Long-term treatment with nisoldipine prevented the development of hypertension, the associated heart failure, and the increase of plasma levels of ANP in SHR but had no effect on systolic blood pressure, heart weight, and plasma levels of ANP in WKY. In addition, nisoldipine had a therapeutic effect in old SHR with manifest cardiac failure in end-stage hypertension, as evidenced not only by the reduction of blood pressure but also by the reduction of cardiac hypertrophy, of elevated immunoreactive ANP in plasma, and of increased plasma renin activity.
No takes yet. Share an insight, caveat, or question.
Stasch et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: